Amylin Pharmaceuticals Reports Second Quarter Financi...( ---- ...),Health

Date:7/21/2009

---- ---- ---- ---- Revenues: Net product sales $197,497 $200,335 $376,829 $379,056 Revenues under collaborative agreements 11,875 21,684 26,217 40,200 ------- ------- ------- ------- Total revenues 209,372 222,019 403,046 419,256 Costs and expenses: Cost of goods sold 24,293 24,682 42,925 46,706 Selling, general and administrative 92,052 111,088 179,608 209,331 Research and development 63,601 75,401 123,620 152,607 Collaborative profit sharing 76,199 78,950 149,216 148,851 Restructuring 11,376 - 11,376 - ------- ------- ------- ------- Total costs and expenses 267,521 290,121 506,745 557,495 Operating loss (58,149) (68,102) (103,699) (138,239) Interest and other (expense) income, net (4,223) 1,511 (5,627) 549 ------- ----- ------- --- Net loss $(62,372) $(66,591) $(109,326) $(137,690) ========= ========= ========== ========== Net loss per share - basic and diluted $(0.44) $(0.49) $(0.78) $(1.01) ======= ======= ======= ======= Shares used in computing net loss per share - basic and diluted 140,912 137,142 139,864 136,500 ======= ======= ======= ======= A reconciliation of reported GAAP operating loss to non-GAAP operating loss excluding non-cash items and
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine news :

1. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
2. Amylin Pharmaceuticals to Webcast Third Quarter Results
3. Amylin Pharmaceuticals to Webcast Conference Call
4. Amylin Pharmaceuticals to Present at Research & Development Day
5. Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals
6. Amylin Pharmaceuticals Reports 2007 Financial Results
7. Amylin Pharmaceuticals Reports First Quarter Financial Results
8. Amylin Pharmaceuticals Diabetes Drug Byetta the Focus of California Lawsuit
9. Lilly and Amylin Set Date and Time for Conference Call
10. Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
11. Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission